Active Pharmaceutical Ingredients
- Industrial Coatings
- Dyes and Pigments
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
- Analytical Chemistry
- Pharmaceutical Intermediates
InnoCare, a biomedical high-tech company, (HKEx: 09969; SSE code: 688428) announced on January 5 that the company will publish the latest research data
on the treatment of cholangiocarcinoma with the FGFR inhibitor Gunagratinib (ICP-192) at the 2023 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI).
The 2023 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI) will be held
online and in-person in San Francisco, USA, January 19-21, 2023.
ASCO GI is the world's authoritative academic exchange event in the field of gastrointestinal cancer, which will showcase innovative scientific research results, strategies and multidisciplinary research methods
in the treatment, research and care of gastrointestinal cancer.
: The highly selective irreversible FGFR inhibitor Gunagratinib in previously treated patients with locally advanced or metastatic FGFR gene abnormalities with cholangiocarcinoma: a phase IIa dose expansion study
Summary code: 572
Sub-venue: Poster venue B: Pancreatic cancer, small bowel cancer and hepatobiliary cancer
When: January 20, 12:00 PM - 1:30 PM US time
: Professor Guo Ye